> Шифр: AE1/2015/26/8 Журнал 2015р. Vol. 26 N 8 Ignatiadis, M. St Gallen International Expert Consensus on the primary therapy of early breast cancer: an invaluable tool for physicians and scientists / M. Ignatiadis, M. Buyse, C. Sotiriou. - P.1519-1520 Azim, H. A. Has the time come for genomic tests to guide the use of adjuvant chemotherapy in node-positive breast cancer? / H. A. Azim. - P.1521-1523 Dienstmann, R. Heterogeneity of driver genes and therapeutic implications in colorectal cancer / R. Dienstmann, A. Cervantes. - P.1523-1525 Montagut, C. Liquid biopsies to evaluate early therapeutic response in colorectal cancer / C. Montagut, G. Siravegna, A. Bardelli. - P.1525-1527 Vansteenkiste, J. Pulmonary carcinoid: a rare thoracic malignancy, a high need for better defined systemic therapy / J. Vansteenkiste. - P.1527-1529 Tabernero, J. Proven efficacy, equitable access, and adjusted pricing of anti-cancer therapies: no ‘sweetheart’ solution / J. Tabernero. - P.1529-1531 Soria, J. -C. ‘Statistical controversies in clinical research’: a new series in Annals of Oncology / J. -C. Soria, M. Buyse. - P.1532 Coates, A. S. Tailoring therapies - improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 / A. S. Coates [и др.]. - P.1533-1546 Інші автори: Winer E. P., Goldhirsch A., Gelber R. D., Gnant M. Cherny, N. I. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) / N. I. Cherny [и др.]. - P.1547-1573 Інші автори: Sullivan R., Dafni U., Kerst J. M., Sobrero A. Eberhardt, W. E. E. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer / W. E. E. Eberhardt [и др.]. - P.1573-1588 Інші автори: De Ruysscher D., Weder W., Le Péchoux C., De Leyn P. Gillessen, S. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 / S. Gillessen [и др.]. - P.1589-1604 Інші автори: Omlin A., Attard G., De Bono J. S., Efstathiou E. Caplin, M. E. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids / M. E. Caplin [и др.]. - P.1604-1620 Інші автори: Baudin E., Ferolla P., Filosso P., Garcia-Yuste M. Thall, P. Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials / P. Thall, P. Fox, J. Wathen. - P.1621-1628 Sonnenblick, A. Adjuvant systemic therapy in breast cancer: quo vadis? / A. Sonnenblick, M. Piccart. - P.1629-1634 Aune, D. Anthropometric factors and endometrial cancer risk: a systematic review and dose–response meta-analysis of prospective studies / D. Aune [и др.]. - P.1635-1648 Інші автори: Navarro Rosenblatt D. A., Chan D. S. M., Vingeliene S., Abar L. Stahel, R. A. Searching for targets for the systemic therapy of mesothelioma / R. A. Stahel [и др.]. - P.1649-1660 Інші автори: Weder W., Felley-Bosco E., Petrausch U., Curioni-Fontecedro A. Fizazi, K. Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra / K. Fizazi, C. Jenkins, I. F. Tannock. - P.1660-1667 Witzig, T. E. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma / T. E. Witzig [и др.]. - P.1667-1677 Інші автори: Nowakowski G. S., Habermann T. M., Goy A., Hernandez-Ilizaliturri F. J. Launay-Vacher, V. Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN) / V. Launay-Vacher [и др.]. - P.1677-1684 Інші автори: Aapro M., De Castro G., Cohen E., Deray G. Gnant, M. Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype / M. Gnant [и др.]. - P.1685-1691 Інші автори: Sestak I., Filipits M., Dowsett M., Balic M. Gonçalves, A. UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel–5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer / A. Gonçalves [и др.]. - P.1692-1697 Інші автори: Pierga J.-Y., Ferrero J.-M., Mouret-Reynier M.-A., Bachelot T. Dieci, M. V. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials / M. V. Dieci [и др.]. - P.1698-1704 Інші автори: Mathieu M. C., Guarneri V., Conte P., Delaloge S. Bidard, F. -C. Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer / F. -C. Bidard [и др.]. - P.1704-1709 Інші автори: Ng C. K. Y., Cottu P., Piscuoglio S., Escalup L. Normanno, N. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial / N. Normanno [и др.]. - P.1710-1714 Інші автори: Rachiglio A. M., Lambiase M., Martinelli E., Fenizia F. Tie, J. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer / J. Tie [и др.]. - P.1715-1722 Інші автори: Kinde I., Wang Y., Wong H. L., Roebert J. Fernandez-Martos, C. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial / C. Fernandez-Martos [и др.]. - P.1722-1728 Інші автори: Garcia-Albeniz X., Pericay C., Maurel J., Aparicio J. Stremitzer, S. Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases / S. Stremitzer [и др.]. - P.1728-1733 Інші автори: Zhang W., Yang D., Ning Y., Stintzing S. Vansteenkiste, J. Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO) / J. Vansteenkiste [и др.]. - P.1734-1740 Інші автори: Barlesi F., Waller C. F., Bennouna J., Gridelli C. Ramalingam, S. A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1) / S. Ramalingam [и др.]. - P.1741-1748 Інші автори: Goss G., Rosell R., Schmid-Bindert G., Zaric B. Fallet, V. High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targets / V. Fallet [и др.]. - P.1748-1753 Інші автори: Saffroy R., Girard N., Mazieres J., Lantuejoul S. Gakis, G. Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma / G. Gakis [и др.]. - P.1754-1759 Інші автори: Morgan T. M., Daneshmand S., Keegan K. A., Todenhöfer T. Ferreri, A. J. M. High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial / A. J. M. Ferreri [и др.]. - P.1760-1765 Інші автори: Sassone M., Kiesewetter B., Govi S., Scarfò L. Shi, Y. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma / Y. Shi [и др.]. - P.1766-1771 Інші автори: Dong M., Hong X., Zhang W., Feng J. Meissner, J. Long-term ovarian function in women treated with CHOP or CHOP plus etoposide for aggressive lymphoma / J. Meissner [и др.]. - P.1771-1776 Інші автори: Tichy D., Katzke V., Kühn T., Dietrich S. Waterhouse, M. Vitamin D and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case–Control Consortium / M. Waterhouse [и др.]. - P.1776-1783 Інші автори: Risch H. A., Bosetti C., Anderson K. E., Petersen G. M. Helby, J. IgE and risk of cancer in 37 747 individuals from the general population / J. Helby [и др.]. - P.1784-1790 Інші автори: Bojesen S. E., Nielsen S. F., Nordestgaard B. G. Rodon, J. Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial / J. Rodon [и др.]. - P.1791-1798 Інші автори: Soria J. C., Berger R., Batist G., Tsimberidou A. Gnant, M. Reply to the letter to the editor ‘Duration of endocrine therapy and its impact on the results of adjuvant trials in premenopausal breast cancer patients’ by Fouad et al. / M. Gnant, P. C. Dubsky. - P.1799-1800 Togashi, Y. An activating ALK gene mutation in ALK IHC-positive/FISH-negative nonsmall-cell lung cancer / Y. Togashi [и др.]. - P.1800-1801 Інші автори: Mizuuchi H., Kobayashi Y., Hayashi H., Terashima M. Ilie, M. Reply to the letter to the editor ‘ALK FISH rearranged and amplified tumor with negative immunohistochemistry: a rare and challenging case concerning ALK status screening in lung cancer’ by Uguen et al. / M. Ilie, P. Hofman. - P.1802 Van, Oijen B. P. C. The first study published? / Oijen B. P. C. Van [и др.]. - P.1803 Інші автори: Erdkamp F. L. G., Schouten H. C., Van der Kuy P. H. M. Є примірники у відділах: всього 1 : ЧЗ (1) Вільні: ЧЗ (1) |